Get the Stockscreener App
16.82
1.88%
0.31
Lyell Immunopharma Inc stock is traded at $16.82, with a volume of 2,964.
It is up +1.88% in the last 24 hours and up +31.20% over the past month.
Lyell Immunopharma Inc is a clinical-stage cell therapy company. It has a pipeline of product candidates for patients with solid tumors utilizing ex vivo genetic and epigenetic T-cell reprogramming technologies. The company's product pipeline includes, LYL797, LYL119, LYL845 among others.
See More
Previous Close:
$16.51
Open:
$16.88
24h Volume:
2,964
Relative Volume:
0.06
Market Cap:
$326.59M
Revenue:
$54,000
Net Income/Loss:
$-210.26M
P/E Ratio:
-21.29
EPS:
-0.79
Net Cash Flow:
$-159.01M
1W Performance:
-5.77%
1M Performance:
+31.20%
6M Performance:
+91.79%
1Y Performance:
-28.73%
1-Day Range:
$16.88
$17.00
1-Week Range:
$16.45
$19.45
52-Week Range:
$7.65
$30.00
Lyell Immunopharma Inc Stock (LYEL) Company Profile
Name
Lyell Immunopharma Inc
Sector
Industry
Phone
650 695-0677
Address
201 HASKINS WAY, SOUTH SAN FRANCISCO
Compare LYEL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LYEL
Lyell Immunopharma Inc
|
17.00 | 317.18M | 54,000 | -210.26M | -159.01M | -0.79 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.42 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
461.45 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
545.17 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
796.67 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
326.40 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Lyell Immunopharma Inc Stock (LYEL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-30-24 | Downgrade | BofA Securities | Buy → Underperform |
| Jun-27-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Aug-28-23 | Downgrade | JP Morgan | Overweight → Neutral |
| Nov-14-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Nov-11-22 | Downgrade | Goldman | Buy → Neutral |
| Oct-17-22 | Initiated | H.C. Wainwright | Buy |
| Jul-12-21 | Initiated | BofA Securities | Buy |
| Jul-12-21 | Initiated | Goldman | Buy |
| Jul-12-21 | Initiated | JP Morgan | Overweight |
| Jul-12-21 | Initiated | Morgan Stanley | Overweight |
View All
Lyell Immunopharma Inc Stock (LYEL) Latest News
Is it too late to sell Lyell Immunopharma Inc.July 2025 Sentiment & Free Risk Controlled Daily Trade Plans - newser.com
How to track smart money flows in Lyell Immunopharma Inc.Portfolio Gains Report & Consistent Income Trade Ideas - newser.com
Tick level data insight on Lyell Immunopharma Inc. volatility2025 Top Gainers & Smart Allocation Stock Tips - newser.com
Is Lyell Immunopharma Inc. showing signs of accumulationMarket Movement Recap & Expert Curated Trade Setup Alerts - newser.com
Is Lyell Immunopharma Inc. forming a reversal pattern2025 Market WrapUp & Long-Term Capital Growth Strategies - newser.com
Lyell Immunopharma (NASDAQ:LYEL) Receives "Sell (D-)" Rating from Weiss Ratings - MarketBeat
Will Lyell Immunopharma Inc. continue its uptrend2025 Market Outlook & Risk Managed Investment Signals - newser.com
Clarius Group LLC Reduces Stake in Lyell Immunopharma, Inc. $LYEL - MarketBeat
Can trapped investors hope for a rebound in Lyell Immunopharma Inc.Long Setup & Technical Pattern Alert System - newser.com
Johnson & Johnson Reduces Stock Holdings in Lyell Immunopharma, Inc. $LYEL - MarketBeat
Smart tools for monitoring Lyell Immunopharma Inc.’s price actionPortfolio Update Summary & Long-Term Safe Investment Plans - newser.com
News impact scoring models applied to Lyell Immunopharma Inc.July 2025 Fed Impact & Technical Buy Zone Confirmations - newser.com
Technical analysis overview for Lyell Immunopharma Inc. stockGlobal Markets & High Conviction Trade Alerts - newser.com
Trend analysis for Lyell Immunopharma Inc. this weekProduct Launch & Free Community Supported Trade Ideas - newser.com
Applying chart zones and confluence areas to Lyell Immunopharma Inc.Earnings Overview Report & Capital Efficiency Focused Strategies - newser.com
Will Lyell Immunopharma Inc. stock deliver long term returns2025 Earnings Impact & High Accuracy Investment Signals - newser.com
Using Ichimoku Cloud for Lyell Immunopharma Inc. technicals2025 Stock Rankings & Community Trade Idea Sharing Platform - newser.com
How moving averages guide Lyell Immunopharma Inc. tradingPortfolio Growth Summary & High Accuracy Swing Entry Alerts - newser.com
Voya Investment Management LLC Sells 2,606 Shares of Lyell Immunopharma, Inc. $LYEL - Defense World
Applying Elliott Wave Theory to Lyell Immunopharma Inc.Market Risk Analysis & Consistent Profit Trading Strategies - newser.com
Goldman Sachs Group Inc. Has $193,000 Position in Lyell Immunopharma, Inc. $LYEL - Defense World
What’s the recovery path for long term holders of Lyell Immunopharma Inc.Weekly Loss Report & Consistent Return Investment Signals - newser.com
Lyell Immunopharma Inc Stock (LYEL) Financials Data
Revenue
Net Income
Cash Flow
EPS
Lyell Immunopharma Inc Stock (LYEL) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Hill Stephen J. | Chief Operating Officer |
Aug 21 '25 |
Sale |
10.54 |
1,004 |
10,586 |
15,845 |
| Newton Charles W. | Chief Financial Officer |
Aug 21 '25 |
Sale |
10.54 |
1,453 |
15,320 |
15,306 |
| Lee Gary K. | Chief Scientific Officer |
Aug 21 '25 |
Sale |
10.54 |
1,453 |
15,320 |
15,504 |
| Seely Lynn | President and CEO |
Aug 12 '25 |
Sale |
10.34 |
406 |
4,197 |
34,828 |
| Seely Lynn | President and CEO |
Aug 11 '25 |
Sale |
10.53 |
391 |
4,116 |
35,234 |
| Hill Stephen J. | Chief Operating Officer |
Aug 12 '25 |
Sale |
10.34 |
94 |
972 |
8,849 |
| Hill Stephen J. | Chief Operating Officer |
Aug 11 '25 |
Sale |
10.53 |
91 |
958 |
8,943 |
| Lee Gary K. | Chief Scientific Officer |
Aug 12 '25 |
Sale |
10.34 |
136 |
1,406 |
8,957 |
| Lee Gary K. | Chief Scientific Officer |
Aug 11 '25 |
Sale |
10.53 |
131 |
1,379 |
9,093 |
| Newton Charles W. | Chief Financial Officer |
Aug 12 '25 |
Sale |
10.34 |
136 |
1,406 |
8,759 |
2.20%
1.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):